FDA-Approved Drugs Under Investigation in Multiple Myeloma for Actionable Targets

The MMRF CureCloud assay uses next-generation sequencing to analyze cell-free DNA (cfDNA) isolated from a patient’s blood sample, to identify clinically relevant genomic alterations based on a unique 70-gene panel. This brochure provides an overview of targeted therapies that are FDA- approved for various tumor types which have activity associated with genomic alterations detected in the CureCloud assay and are under investigation in multiple myeloma.

This information is intended to provide context for the results of the CureCloud assay and is not intended to be treatment recommendations. The report that you will receive for patients enrolled in CureCloud should be considered in context with other clinical criteria (e.g., patient history, physical exam), as well as laboratory, pathology, and imaging studies. The selection of any drugs or clinical trials is entirely at the discretion of the treating medical professional.

FDA-Approved Drugs for Actionable Targets in Multiple Myeloma (Last update 03/2020) Page 1 Actionable in Multiple Myeloma and Associated FDA-Approved Targeted Drugs

Altered Gene in MM (Type of Alteration) FDA-Approved Targeted Drugs

BCL2 (Overexpression) VENCLEXTA () BRAF (non-V600) COTELLIC () MEKINIST () STIVARGA () TAFINLAR () CCND1 (Translocation and overexpression) IBRANCE () KISQALI () VENCLEXTA (venetoclax) VERZENIO () CCND2 (Overexpression) IBRANCE (palbociclib) VERZENIO (abemaciclib) CDKN2A (Deficiency) IBRANCE (palbociclib) CYLD (Loss) VENCLEXTA (venetoclax) ZOLINZA () FGFR3 (Translocation and overexpression) BALVERSA () ICLUSIG () High burden IMFINZI () KEYTRUDA () IDH1 TIBSOVO () VENCLEXTA (venetoclax) IDH2 (p.R172K) IDHIFA () KRAS (Activating) COTELLIC (cobimetinib) MEKINIST (trametinib) TAFINLAR (dabrafenib) ZELBORAF () NF1 (p.v341fs and copy loss LOH) MEKINIST (trametinib) NRAS (Activating) COTELLIC (cobimetinib) MEKINIST (trametinib) MEKTOVI () TAFINLAR (dabrafenib) ZELBORAF (vemurafenib)

FDA-Approved Drugs for Actionable Targets in Multiple Myeloma (Last update 03/2020) Page 2 Clinical Trials of FDA-Approved Targeted Drugs for Actionable Mutations in Myeloma

Drug Name Route of FDA-Approved Altered Gene in MM Clinical Trials in MM Data in MM Administration Indication (Type of Alteration) (Level of Evidence)*

BALVERSA Oral tablet Locally advanced or metastatic urothelial FGFR3 (Translocation • Myeloma-Developing Regimens Using Genomics NA (erdafitinib) carcinoma and overexpression) (MyDRUG) (NCT03732703) • Testing JNJ-42756493 In Combination With in MM That Came Back After a Period of Improvement (NCT02952573) • NCI-MATCH: Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or (NCT02465060) COTELLIC Oral tablet In combination with ZELBORAF BRAF (non-V600) Myeloma-Developing Regimens Using Genomics (MyDRUG) Level 5[1] (cobimetinib) (vemurafenib): unresectable or metastatic (NCT03732703) KRAS (Activating) Myeloma-Developing Regimens Using Genomics (MyDRUG) (NCT03732703) NRAS (Activating) Myeloma-Developing Regimens Using Genomics (MyDRUG) (NCT03732703) IBRANCE Oral capsule In combination with an CCND1 (Translocation • NCI-MATCH: Targeted Therapy Directed by Genetic Level 2[2] (palbociclib) or : HR-positive, HER2-negative and overexpression) Testing in Treating Patients With Advanced Refractory advanced or metastatic Solid Tumors or Lymphomas (NCT02465060) • Phase II trial of the cyclin-dependent kinase inhibitor PD 0332991 in patients with cancer (NCT01037790) CCND2 Phase II trial of the cyclin-dependent kinase inhibitor PD (Overexpression) 0332991 in patients with cancer (NCT01037790) CDKN2A (Deficiency) TAPUR: Testing the Use of FDA Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535) ICLUSIG (ponatinib) Oral tablet Chronic phase, accelerated phase, or blast FGFR3 (Translocation Ponatinib Hydrochloride in Treating Patients With Refractory NA phase CML or Ph+ ALL (± T315I) and overexpression) Metastatic Cancers and Genetic Alterations (NCT02272998) IDHIFA (enasidenib) Oral tablet Relapsed or refractory AML IDH2 (p.R172K) Myeloma-Developing Regimens Using Genomics (MyDRUG) NA (NCT03732703) IMFINZI Intravenous Locally advanced or metastatic urothelial High mutation burden A phase 2 study to determine the safety and efficacy for the PK study[3] (durvalumab) injection carcinoma combination of Durvalumab and in RRMM (NCT02807454)

FDA-Approved Drugs for Actionable Targets in Multiple Myeloma (Last update 03/2020) Page 3 Drug Name Route of FDA-Approved Altered Gene in MM Clinical Trials in MM Data in MM Administration Indication (Type of Alteration) (Level of Evidence)*

KEYTRUDA Intravenous • Unresectable or metastatic High mutation burden • Phase 2 Multi-center Study of Anti-PD-1 During Level 5[4] (pembrolizumab) injection melanoma Lymphopenic State After HDT/ASCT for Multiple Level 3[5,6] • Adjuvant treatment of melanoma Myeloma (NCT02331368) Level 2[7-15] • NSCLC • A study of Pembrolizumab in combination with standard Level 1[16] • SCLC of care treatments in participants with Multiple • HNSCC Myeloma (NCT02036502) • cHL • TAPUR: Testing the Use of FDA Approved Drugs That • Primary mediastinal LBCL Target a Specific Abnormality in a Tumor Gene in People • Urothelial carcinoma With Advanced Stage Cancer (NCT02693535) • Microsatellite instability-high cancer • Efficacy and safety study of Pembrolizumab in • Gastric cancer combination with Daratumumab in participants with • Esophageal cancer relapsed refractory Multiple Myeloma (NCT03221634) • Cervical cancer • HCC • Merkel cell carcinoma • RCC • Endometrial carcinoma KISQALI (ribociclib) Oral tablet In combination with an aromatase inhibitor CCND1 (Translocation LEE011 for Patients With CDK4/6 Pathway Activated NA or fulvestrant: HR-positive, HER2-negative and overexpression) Tumors (NCT02187783) advanced or MEKINIST Oral tablet In combination with TAFINLAR (dabrafenib): BRAF (non-V600) • A Study of Dabrafenib and/or Trametinib in Patients Level 5[17-20] (trametinib) • Unresectable or metastatic melanoma With RRMM (NCT03091257) Level 4[21] • The adjuvant treatment of melanoma • NCI-MATCH: Targeted Therapy Directed by Genetic • Metastatic NSCLC Testing in Treating Patients With Advanced Refractory • Locally advanced or metastatic anaplastic Solid Tumors or Lymphomas (NCT02465060) thyroid cancer KRAS (Activating) A Study of Dabrafenib and/or Trametinib in Patients With RRMM (NCT03091257) NF1 (p.v341fs and • NCI-MATCH: Targeted Therapy Directed by Genetic copy loss LOH) Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas (NCT02465060) • Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With RRMM (NCT01989598) NRAS (Activating) A Study of Dabrafenib and/or Trametinib in Patients With RRMM (NCT03091257) MEKTOVI Oral tablet In combination with BRAFTOVI NRAS (Activating) NCI-MATCH: Targeted Therapy Directed by Genetic Testing NA (binimetinib) (): unresectable or metastatic in Treating Patients With Advanced Refractory Solid Tumors melanoma or Lymphomas (NCT02465060) STIVARGA Oral tablet • Metastatic CRC BRAF (non-V600) TAPUR: Testing the Use of FDA Approved Drugs That Target NA (regorafenib) • Locally advanced, unresectable or a Specific Abnormality in a Tumor Gene in People With metastatic GIST Advanced Stage Cancer (NCT02693535) • HCC

FDA-Approved Drugs for Actionable Targets in Multiple Myeloma (Last update 03/2020) Page 4 Drug Name Route of FDA-Approved Altered Gene in MM Clinical Trials in MM Data in MM Administration Indication (Type of Alteration) (Level of Evidence)*

TAFINLAR Oral capsule Single agent: unresectable or metastatic BRAF (non-V600) A Study of Dabrafenib and/or Trametinib in Patients With Level 5[20] (dabrafenib) melanoma RRMM (NCT03091257) Level 4[21]

In combination with MEKINIST (trametinib): KRAS (Activating) A Study of Dabrafenib and/or Trametinib in Patients With • Unresectable or metastatic melanoma RRMM (NCT03091257) • Adjuvant treatment of melanoma • Metastatic NSCLC NRAS (Activating) A Study of Dabrafenib and/or Trametinib in Patients With • Locally advanced or metastatic RRMM (NCT03091257) anaplastic thyroid cancer TIBSOVO Oral tablet Newly diagnosed or relapsed or refractory IDH1 Phase Ib/II Investigator sponsored study of the IDH1- NA (ivosidenib) AML mutant inhibitor Ivosidenib (AG120) with the BCL2 inhibitor Venetoclax in IDH1-Mutated Hematologic Malignancies (NCT03471260) VENCLEXTA Oral tablet Single agent: CLL or SLL BCL2 • Study of Venetoclax in Combination With Real-world (venetoclax) (Overexpression) and Dexamethasone in Subjects With RRMM evidence[22-24] In combination with or (NCT02899052) Level 5[25-27] or low-dose : newly • A Study of Venetoclax and Dexamethasone Compared Level 4[21,28] diagnosed AML With Pomalidomide and Dexamethasone in Subjects Level 3[29,30] With RRMM (CANOVA) (NCT03539744) Level 2[31-38] • A Study of Combination Therapy With Venetoclax, Level 1[39,40] Daratumumab and Dexamethasone (With and Without ) in Subjects With RRMM (NCT03314181) CCND1 (Translocation Myeloma-Developing Regimens Using Genomics (MyDRUG) and overexpression) (NCT03732703) CYLD (Loss) Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT02899052) IDH1 Phase Ib/II Investigator sponsored study of the IDH1- mutant inhibitor Ivosidenib (AG120) with the BCL2 inhibitor Venetoclax in IDH1-Mutated Hematologic Malignancies (NCT03471260) VERZENIO Oral tablet In combination with an aromatase inhibitor CCND1 (Translocation Myeloma-Developing Regimens Using Genomics (MyDRUG) NA (abemaciclib) or fulvestrant: HR-positive, HER2-negative and overexpression) (NCT03732703) advanced or metastatic breast cancer CCND2 Myeloma-Developing Regimens Using Genomics (MyDRUG) (Overexpression) (NCT03732703)

FDA-Approved Drugs for Actionable Targets in Multiple Myeloma (Last update 03/2020) Page 5 Drug Name Route of FDA-Approved Altered Gene in MM Clinical Trials in MM Data in MM Administration Indication (Type of Alteration) (Level of Evidence)*

ZELBORAF Oral tablet • Unresectable or metastatic melanoma KRAS (Activating) • TAPUR: Testing the Use of Food and Drug Level 5[1,41-43] (vemurafenib) • Erdheim-Chester Disease Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535) • Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606) NRAS (Activating) • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535) • Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606) ZOLINZA Oral capsule Progressive, persistent or recurrent CTCL CYLD (Loss) A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, Level 4[44,45] (vorinostat) and Dexamethasone in Relapsed and/or Refractory Multiple Level 2[46-63] Myeloma (NCT01297764) Level 1[64]

*Review of the published literature and abstracts from the International Myeloma Workshop 2019 and the American Society of Hematology 2016–2019.

Levels of Evidence for Therapeutic Studies65

Level Type of evidence

1 Systematic review (with homogeneity) of RCTs Individual RCT (with narrow confidence intervals) All or none study 2 Systematic review (with homogeneity) of cohort studies Individual Cohort study (including low quality RCT, e.g. <80% follow-up) “Outcomes” research; Ecological studies 3 Systematic review (with homogeneity) of case-control studies Individual Case-control study 4 Case series (and poor quality cohort and case-control study) 5 Case report Expert opinion without explicit critical appraisal or based on physiology bench research or “first principles”

FDA-Approved Drugs for Actionable Targets in Multiple Myeloma (Last update 03/2020) Page 6 References

1. Mey UJM et al. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple 2017;130(22):2401-2409. 34. Moreau P et al. Promising efficacy and acceptable safety of venetoclax plus myeloma harboring the BRAF mutation. Hematol Oncol. 2017;35(4):890-893. 2. Niesvizky R et al. Phase 1/2 bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392-2400. 35. Bahlis N et al. study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and First analysis from a phase 1/2 study of venetoclax in combination with daratumumab and dexamethasone, +/- dexamethasone in relapsed/refractory multiple myeloma. Leuk . 2015;56(12):3320-8. 3. Ogasawara K, et bortezomib, in patients with relapsed/refractory multiple myeloma. Blood. 2019;134: Abstract 925. 36. Kaufman JL al. Population of an anti-PD-L1 antibody, durvalumab in patients with hematologic malignancies. et al. Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed/ Clin Pharmacokinet. 2020;59(2):217-227. 4. Bryant AR et al. Severe pembrolizumab-associated after refractory multiple myeloma. Blood. 2017;130: Abstract 3131. 37. Kaufman JL et al. Phase I/II study evaluating the CD34(+) selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bone Marrow Transplant. safety and efficacy of venetoclax in combination with dexamethasone as targeted therapy for patients with t(11;14) 2018;53(8):1065-1068. 5. Wilson L et al. Pembrolizumab in combination with pomalidomide and dexamethasone relapsed/refractory multiple myeloma. Blood. 2019;134: Abstract 926. 38. Costa LJ et al. Phase 2 study of (PEMBRO/POM/DEX) for pomalidomide exposed relapsed or refractory multiple myeloma. Blood. 2016;128: venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.Blood. Abstract 2119. 6. Bernabei L et al. PD-1 inhibitor combinations as salvage therapy for relapsed/refractory multiple 2018;132: Abstract 303. 39. Kumar S et al. A phase 3 study of venetoclax or placebo in combination with myeloma (MM) patients progressing after BCMA-directed CAR T cells. Blood. 2018;132: Abstract 1973. 7. Badros A bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Presented at the 17th et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. International Myeloma Workshop; September 12–15, 2019. Abstract OAB-045. 40. Gasparetto C et al. Physical Blood. 2017;130(10):1189-1197. 8. Badros AZ et al. Long-term remissions after stopping pembrolizumab for function, pain severity, and fatigue in patients with relapsed/refractory multiple myeloma: health-related quality of relapsed or refractory multiple myeloma. Blood Adv. 2019;3(11):1658-1660. 9. D’Souza A et al. A phase 2 study of life results in patients receiving venetoclax or placebo in combination with bortezomib and dexamethasone. Blood. pembrolizumab during lymphodepletion after autologous hematopoietic cell transplantation for multiple myeloma. 2019;134: Abstract 3177. 41. Sharman JP et al. Vemurafenib response in 2 patients with posttransplant refractory Biol Blood Marrow Transplant. 2019;25(8):1492-1497. 10. Mateos MV et al. Pembrolizumab combined with BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14(5):e161-3. 42. Andrulis M et al. lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013 Aug;3(8):862-9. 43. Raje N et al. study. Br J Haematol. 2019;186(5):e117-e121. 11. Ribrag V et al. Phase 1b trial of pembrolizumab monotherapy for Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAFV600 Mutations: a cohort of relapsed/refractory multiple myeloma: KEYNOTE-013. Br J Haematol. 2019;186(3):e41-e44. 12. Nishihori T et al. the histology-independent VE-BASKET study. JCO Precis Oncol. 2018. 44. Bilotti E et al. Vorinostat in Combination Open-label pilot study of genetically engineered NY-ESO-1 specific T Cells (GSK3377794) alone or in combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Clin Lymphoma Myeloma with pembrolizumab in relapsed and refractory multiple myeloma. Blood. 2019;134: Abstract 3134. 13. Bansal M et Leuk. 2016;16(10):558-562. 45. Mazumder A et al. Vorinostat plus bortezomib for the treatment of relapsed/ al. Two year update of phase II trial of pembrolizumab, lenalidomide and dexamethasone as post -autologous stem refractory multiple myeloma: a case series illustrating utility in clinical practice. Clin Lymphoma Myeloma Leuk. cell transplant consolidation in patients with high-risk multiple myeloma. Blood. 2019;134: Abstract 1911. 14. Biran 2010;10(2):149-51. 46. Badros A et al. Phase I study of vorinostat in combination with bortezomib for relapsed and N et al. A phase II trial of the anti -PD-1 monoclonal antibody pembrolizumab (MK-3475) + lenalidomide + refractory multiple myeloma. Clin Cancer Res. 2009;15(16):5250-7. 47. Gao X et al. Efficacy and toxicity of histone dexamethasone as post autologous stem cell transplant consolidation in patients with high-risk multiple myeloma. deacetylase inhibitors in relapsed/refractory multiple myeloma: systematic review and meta-analysis of clinical Blood. 2017;130: Abstract 1831. 15. Ocio EM et al. Immune predictors of response to pembrolizumab monotherapy trials. Exp Ther Med. 2019;18(2):1057-1068. 48. Holmberg LA et al. Bortezomib and vorinostat therapy as as consolidation in multiple myeloma patients: results of the GEM-pembresid . Blood. 2017;130: maintenance therapy after autologous transplant for multiple myeloma. Acta Haematol. 2019:1-9. 49. Ogawa Y et al. Abstract 1874. 16. Mateos MV et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. myeloma. Int J Hematol. 2016;103(1):25-33. 50. Richardson P et al. Phase I trial of oral vorinostat (suberoylanilide 2019;6(9):e459-e469. 17. Tolcher AW et al. Phase I study of the MEK inhibitor trametinib in combination with the hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49(3):502-7. 51. AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol. Sanchez L et al. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with 2015;75(1):183-9. 18. Cengiz Seval G et al. Next generation sequencing may be helpful in designing novel multiple myeloma refractory to previous lenalidomide-containing regimens. Br J Haematol. 2017;176(3):440-447. combinations among heavily pretreated myeloma patients, refractory to all available approved anti-myeloma drugs. 52. Sborov DW et al. Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br Blood. 2019;134: Abstract 3197. 19. Heuck CJ et al. Inhibiting MEK in MAPK pathway-activated myeloma. . J Haematol. 2015;171(1):74-83. 53. Sharma N et al. Lenalidomide and vorinostat maintenance after autologous 2016;30(4):976-80. 20. Da Vià MC et al. CIC mutation as a molecular mechanism of acquired resistance to transplantation in multiple myeloma: long-term follow-up. Biol Blood Marrow Transplant. 2020;26(1):44-49. 54. combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement. Siegel DS et al. VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in Oncologist. 2019 Oct 18. [Epub ahead of print]. 21. Laganà A et al. Precision medicine for relapsed multiple myeloma combination with bortezomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma on the basis of an integrative multiomics approach. JCO Precis Oncol. 2018;2018. 22. Basali D et al. Real-world data Leuk. 2016;16(6):329-334. 55. Siegel DS et al. Vorinostat in combination with lenalidomide and dexamethasone in on safety and efficacy of venetoclax-based regimens in relapsed/refractory t[11;14] multiple myeloma.Blood. patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014;4:e182. 56. Vesole DH et al. Phase I 2019;134: Abstract 5566. 23. Kumar SK et al. Outcomes of patients with t(11;14) multiple myeloma: an study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory International Myeloma Working Group multicenter study. Blood. 2019;134: Abstract 3066. 24. Sidiqi MH et al. multiple myeloma. Br J Haematol. 2015;171(1):52-9. 57. Voorhees PM et al. Final results of a phase 1 Study of Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials. Presented at the 17th vorinostat, pegylated liposomal , and bortezomib in relapsed or refractory multiple myeloma. Clin International Myeloma Workshop; September 12–15, 2019. Abstract SP-132. 25. Swan D et al. Successful Lymphoma Myeloma Leuk. 2017;17(7):424-432. 58. Waldschmidt JM et al. Safety and efficacy of vorinostat, venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). Haematologica. bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma 2019 Nov 21 [Epub ahead of print]. 26. Bojtine Kovacs S et al. Venetoclax in combination with carfilzomib, (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).Haematologica. doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma 2018;103(10):e473-e479. 59. Weber DM et al. Phase I trial of vorinostat combined with bortezomib for the patient. Haematologica. 2019 Aug 29 [Epub ahead of print]. 27. Touzeau C et al. Deep and sustained response after treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12(5):319-24. 60. venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica. Aslam S et al. Clinical efficacy of intracellular molecular inhibitors for relapsed, refractory multiple myeloma: a 2017;102(3):e112-e114. 28. Bernabei L et al. Infectious complications following Venetoclax- systematic review of early clinical data. Blood. 2018;132: Abstract 1950. 61. Deen IU et al. A decade of drug based regimens in relapsed myeloma: a single center retrospective analysis. Presented at the 17th International development through phase-1 trials; systematic review of literature for novel drugs and targets in multiple Myeloma Workshop; September 12–15, 2019. Abstract FP-121. 29. Kambhampati S et al. A single-center myeloma. Blood. 2017;130: Abstract 5399. 62. Samuel S et al. Efficacy and safety of histone deacetylase inhibitors in retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2020:1-9. 30. multiple myeloma - a systematic review of early phase clinical trials. Blood. 2018;132: Abstract 5629. 63. Sardar M Tor Sauter C et al. Infectious complications following venetoclax-proteasome inhibitor based regimens in relapsed et al. Impact of newer agents on progression free survival of multiple myeloma in the 2nd 3rd and 4th line setting- a myeloma: a single center retrospective analysis. Blood. 2019;134: Abstract 5598. 31. Durer C et al. Safety and systematic review. Blood. 2018;132: Abstract 5645. 64. Dimopoulos M et al. Vorinostat or placebo in combination efficacy of venetoclax in relapsed refractory multiple myeloma: a systematic review and meta-analysis. Blood. with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. 2018;132: Abstract 5625. 32. Rahbari KJ et al. Venetoclax in combination with bortezomib, dexamethasone, and Lancet Oncol. 2013;14(11):1129-1140. 65. Burns PB et al. The levels of evidence and their role in evidence-based daratumumab for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(9):e339-e343. 33. Kumar S et al. medicine. Plast Reconstr Surg. 2011;128(1):305-310. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.Blood.

FDA-Approved Drugs for Actionable Targets in Multiple Myeloma (Last update 03/2020) Page 7